Viloxazine Under Review for ADHD Treatment in Adults neurologyadvisor.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from neurologyadvisor.com Daily Mail and Mail on Sunday newspapers.
Global Celiac Disease Market Insight, Epidemiology and Market Forecast - 2030 benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Met primary endpoint with robust statistical significance
Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical significance
Showed statistically significant onset of action as early as week 2
Had a good safety and tolerability profile throughout the study
Topline data confirm positive results from prior Phase IIa study in adults and Phase III studies of SPN-812 in children and adolescents
ROCKVILLE, Md., Dec. 22, 2020 (GLOBE NEWSWIRE) Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults (P306) for the treatment of attention deficit hyperactivity disorder (ADHD).